Immunotherapy for Head and Neck Cancer: Where do We Go from Here?
Authors:
- 27 November 2023
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (18) , 1497-1500
Abstract
Tweetable abstract Immunotherapy for head and neck cancer shows promising new directions – and challenges ahead. What can we learn from recent trials to improve patient selection and optimize combi...Keywords
Funding Information
- Bicara, BMS and Regeneron
This publication has 20 references indexed in Scilit:
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 2019
- The molecular landscape of head and neck cancerNature Reviews Cancer, 2018
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJournal of Clinical Oncology, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008